Alpha2-antiplasmin is a critical regulator of angiotensin II-mediated vascular remodeling

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 7, 2008, Pages 1257-1262

  Hou, Yongzhong ^a   Okada, Kiyotaka ^a   Okamoto, Chikako ^a   Ueshima, Shigeru ^b,c   Matsuo, Osamu ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KINKI UNIVERSITY   (Japan)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Alpha2 antiplasmin; Ang II; L NAME; Perivascular fibrosis; Vascular remodeling

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANGIOTENSIN II; COLLAGEN TYPE 1; N(G) NITROARGININE METHYL ESTER; PROTEIN P21; PROTEIN P53; BCL2 PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; EYE PROTEIN; GELATINASE; MYC PROTEIN; MYC PROTEIN, MOUSE; NERVE GROWTH FACTOR; ONCOPROTEIN; PIGMENT EPITHELIUM DERIVED FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD VESSEL REACTIVITY; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; MALE; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR FIBROSIS; WILD TYPE; ANIMAL; C57BL MOUSE; CARDIOMEGALY; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; ENZYMOLOGY; FIBROSIS; GENETICS; HEART MUSCLE; HYPERTENSION; MAMMARY ARTERY; METABOLISM; MOUSE MUTANT; PATHOLOGY;

ANGIOTENSIN II; ANIMALS; APOPTOSIS; CARDIOMEGALY; CELL PROLIFERATION; COLLAGEN TYPE I; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE MODELS, ANIMAL; EYE PROTEINS; FIBROSIS; GELATINASES; HYPERTENSION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; NERVE GROWTH FACTORS; NG-NITROARGININE METHYL ESTER; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; SERPINS; THORACIC ARTERIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 46249127599     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.165688     Document Type: Article

References (36)

1. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell. Physiol. 2007;292:82-97.
2. Zhan Y, Brown C, Maynard E, Anshelevich A, Ni W, Ho IC, Oettgen P. Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest. 2005;115:2508-2516.
3. Izumiya Y, Kim. S, Izumi Y, Yoshida K, Yoshiyama M, Matsuzawa A, Ichijo H, Iwao H. Apoptosis signal-regulating kinase 1 plays a pivotal role in. angiotensin II induced cardiac hypertrophy and remodeling. Circ Res. 2003;93:874-883.
4. Menoud PA, Sappino N, Boudal-Rhoshbeen M, Vassalli JD, Sappino AP. The kidney is a major site of alpha(2)-antiplasmin production. J Clin Invest. 1996;97:2478-2484.
5. Coughlin PB. Antiplasmin: The forgotten serpin? FEBS J. 2005;272: 4852-4857.
6. Wiman B, Collen D. Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma. Eur J Biochem, 1977;78:19-26.
7. Carmeliet P, Collen D. Gene manipulation and transfer of the plasminogen and coagulation system in mice. Semin. Thromb Hemost. 1996;22: 525-542.
8. Montes R, Paramo JA, Angles-Cano E, Rocha E. Development and clinical application of a new ELISA assay to determine plasmin-alpha2antiplasmin complexes in plasma. Br J Haematol. 1996;92:979-985.
9. Bayes-Genis A, Guindo J, Oliver A. Elevated, levels of plasmin-alpha 2 antiplasmin complexes in unstable angina. Throm Haemost. 1999;81: 865-868.
10. Lee KN, Tae WC, Jackson. KW, Rwon SH, McRee PA. Characterization of wild-type and mutant a2-antiplasmin: fibrinolysis enhancement by reactive site mutant. Blood. 1999;94:164-171.
11. Sakata Y, Eguchi Y, Mimuro J, Matsuda M, Sumi Y. Clot lysis induced by a monoclonal antibody against alpha2-plasmin inhibitor. Blood. 1989; 74:2692-2697.
12. Matsuno H, Ishisaki A, Nakajima K, Okada K, Ueshima S, Matsuo O, Rozawa O. Lack of (alpha)2-antiplasmin promotes re-endothelialization via over-release of VEGF after vascular injury in mice. Blood. 2003; 102: 3621-3628.
13. Kanno Y, kuroki A, Okada K, Tomogane K, Ueshima S, Matsuo O, Matsuno H. Alpha2-antiplasmin is involved in the production, of transforming growth factor betal and fibrosis. J Thromb Haemost. 2007 ;5: 2266-2273.
14. 2- antiplasmin gene. Throm Haemost. 1997;78:1104-1110.
15. Kaikita K, Fogo AB, Ma L, Schoenhard JA, Brawn NJ, Vaughan DE. Plasminogen, activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation. 2001;104:839-844.
16. Lijnen HR, Okada K, Matsuo O, Collen D. Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood. 1999;93:2274-2281.
17. Gasche Y, Copin JC, Sugawara T, Fujimura M, Chan PH. Matrix metalloprotemase inhibition prevents oxidative stress-associated blood-brain barrier disruption, after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2001;21:1393-1400.
18. Chakraborti S, Mandai M, Das S, Mandai A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell. Biochem, 2003;253: 269-285.
19. Quasnichka H, Slater SC, Beeching CA, Boehm M, Sala-Newby GB, George SJ. Regulation of smooth muscle cell proliferation by betacatenin/T-cell factor signaling involves modulation of cyclin D1 and p21 expression, Circ Res. 2006;99:1329-1337.
20. Hou YZ, Okamoto C, Okada K, K, Naoyaki K, Ueshima S, Matsu O. c-Myc is essential for urokinase plasminogen activator expression on hypoxia induced vascular smooth muscle cells. Cardiovas Res. 2007;75: 186-194.
21. Satoh M, Ogita H, Takeshita K, Mukai Y, Kwiatkowski DJ, Liao JK. Requirement of Racl in the development of cardiac hypertrophy. Proc Natl Acad Sci USA. 2006;103:7432-7437.
22. Huggins CE, Domenighetti AA, Pedrazzini T, Pepe S, Delbridge LM. Elevated intracardiac angiotensin. II leads to cardiac hypertrophy and mechanical dysfunction in normotensive mice. J Renin Angiotensin Aldosterone Syst. 2003;4:186-190.
23. Rugale C, Delbosc S, Cristol JP, Mimran A, Jover B. Sodium restriction, prevents cardiac hypertrophy and oxidative stress in angio-tensin II hypertension. Am J Physiol Heart Circ Physiol. 2003;284: H1744-H1750.
24. Campbell JE, Janicki JS, Weber KT. Temporal differences in fibroblast proliferation, and phenotype expression, in response to chronic administration of angiotensin II or aldosterone J Mol Cell Cardiol. 1995;27: 1545-1560.
25. Weber KT, Brilla CG, Janicki S. Myocardial fibrosis: functional signifi canee and regulatory factors. Cardiovasc Res. 1993;27:341-348.
26. Siuijter JP, de Rleijn DP, Pasterkamp G. Vascular remodeling and protease inhibition-bench to bedside. Cardiovas Res. 2006;69:595-603.
27. Creemers EEJM, Cleutjens J, Smits JFM, Daemen MJAP. Matrix metalloproteinases after myocardial infarctiona new approach to prevent heart failure. Circ Res. 2001;89:201-210.
28. Collen D. The plasminogen (fibrinolytic) system, Thromb Haem, 1999; 82:259-270.
29. Raikita K, Schoenhard JA, Painter CA, Ripley RT, Brown NJ, Fogo AB, Vaughan. DE. Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition. J Mol Cell Cardiol. 2002;34:617-627.
30. Shipley JM, Doyle GA, Fliszar CJ, Ye QZ, Johnson LL, Shapiro SD, Welgus HG, Senior RM. The structural basis for the elastolytic activity of the 92-kDa and 72-kDa gelatinases. Role of the fibronectin type II-like repeats. J Biol Chem, 1996;271:4335-4341.
31. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
32. Nathe TJ, Deou J, Walsh B, Bourns B, Clowes AW, Daum G. Interleukin-1 beta inhibits expression of p21(WAFl/CIPl) andp27(RIPl) and enhanced proliferation in response to platelet-derived growth. factor-BB in smooth muscle cells. Arterioscler Throm Vase Biol. 2002;22: 1293-1298.
33. Tanner FC, Boehm M, Akyurek LM, San H, Yang ZY, Tashiro J, Nabel GJ, Nabel EG. Deferential effeots of the cyclindependent kinase inhibitors p27kip, p21cipl, pl6ink4 on. vascular smooth, muscle cell proliferation. Circulation. 2000;101:2022-2025.
34. Yang ZY, Simari RD, Perkins ND, San H, Gordon D, Nabel GJ, Nabel EG. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimai cell proliferation in response to arterial injury. Proc Natl Acad Sci USA. 1996;9:7905-7910.
35. Rhoury J, Langleben. D. Heparin-like molecules inhibit pulmonary vascular periocyte proliferation in vitro. Am J Physiol Lung Cell Mol. Physiol. 2000;279:L252-L261.
36. Grishko V, Pastukh V, Solodushko V, Gillespie M, Azuma J, Scharfer S. Apoptotic cascade initiated by angiotensin II in neonatal cardiomyocytes: role of DNA damage. Am J Physiol Heart Circ Physiol. 2003;285: H2364-2372.